Singapore markets open in 8 hours 9 minutes
Straits Times Index
3,303.66 +12.96 (+0.39%) S&P 500
5,224.95 +2.27 (+0.04%) Dow
39,498.00 -14.84 (-0.04%) Nasdaq
16,394.87 +54.00 (+0.33%) Bitcoin USD
63,107.94 +1,537.35 (+2.50%) CMC Crypto 200
1,303.38 +43.17 (+3.43%)
PT Kalbe Farma Tbk. (PTKFF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
As of 03:33PM EDT. Market open.
| Previous close | 0.0926 |
| Open | 0.0926 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.0926 - 0.0926 |
| 52-week range | 0.0900 - 0.1456 |
| Volume | |
| Avg. volume | 237 |
| Market cap | 4.283B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | ∞ |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.00 (2.74%) |
| Ex-dividend date | 12 May 2023 |
| 1y target est | N/A |
- Business Wire
Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)
SEOUL, South Korea, October 23, 2023--Genexine (KQ 095700, CEO Sungjune Hong), a publicly-listed clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, together with PT Kalbe Genexine Biologics (KGbio), a joint venture clinical-stage biotechnology company between Genexine and PT Kalbe Farma that focused on bringing biologics medical innovation to international markets, announced the approval of its
© 2024 Yahoo. All rights reserved.